Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat
P Vavrinec, RH Henning, SW Landheer… - Current Vascular …, 2014 - ingentaconnect.com
Type 2 diabetes mellitus (T2DM) is associated with risk for chronic kidney disease (CKD),
which is associated with a decrease in renal myogenic tone-part of renal autoregulatory …
which is associated with a decrease in renal myogenic tone-part of renal autoregulatory …
Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice
HM Salim, D Fukuda, Y Higashikuni, K Tanaka… - Vascular …, 2016 - Elsevier
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have vasoprotective effects.
This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina) …
This study investigated whether a recently approved DPP-4 inhibitor, linagliptin (Lina) …
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience
Various factors may confound how diabetes medications affect a patient's weight. Agents
that induce hypoglycemia may promote weight gain through “defensive eating”. Conversely …
that induce hypoglycemia may promote weight gain through “defensive eating”. Conversely …
Anagliptin, a dipeptidyl peptidase-4 inhibitor ameliorates arterial stiffness in association with reduction of remnant-like particle cholesterol and alanine transaminase …
N Tahara, S Yamagishi, M Bekki… - Current Vascular …, 2016 - ingentaconnect.com
Background: Inhibition of dipeptidyl peptidase-4 (DPP-4) has been proposed as a
therapeutic target for type 2 diabetes (T2DM). Arterial stiffness, a predictor of future …
therapeutic target for type 2 diabetes (T2DM). Arterial stiffness, a predictor of future …
[HTML][HTML] Protective effect of sitagliptin and rosuvastatin combination on vascular endothelial dysfunction in type-2 diabetes
VS Nade, LA Kawale, KM Patel - Indian journal of pharmaceutical …, 2015 - ncbi.nlm.nih.gov
The present investigation aimed to evaluate the protective effects of sitagliptin, glimepiride,
rosuvastatin and their combinations on oxidative stress and endothelial dysfunction in the …
rosuvastatin and their combinations on oxidative stress and endothelial dysfunction in the …
Modulation of Sirt1/NF-κB interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque …
Evogliptin is a novel, potent and selective dipeptidyl peptidase 4 inhibitor that has received
approval for use in the treatment of type 2 diabetes in South Korea. In the management of …
approval for use in the treatment of type 2 diabetes in South Korea. In the management of …
Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic …
HM Salim, D Fukuda, Y Higashikuni, K Tanaka… - Vascular …, 2017 - Elsevier
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors have various cellular effects
that are associated with vascular protection. Here, we examined whether teneligliptin alters …
that are associated with vascular protection. Here, we examined whether teneligliptin alters …
Effect of vildagliptin on hepatic steatosis
M Macauley, KG Hollingsworth, FE Smith… - The Journal of …, 2015 - academic.oup.com
Context: Although dipeptidyl-peptidase-4 inhibitors exert their major action via an incretin
mechanism, a favorable effect of vildagliptin on lipid metabolism remains unexplained …
mechanism, a favorable effect of vildagliptin on lipid metabolism remains unexplained …
Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized …
T Koyama, A Tanaka, H Yoshida, J Oyama, S Toyoda… - Heart and Vessels, 2018 - Springer
Endothelial dysfunction contributes to poor cardiovascular prognosis in patients with type 2
diabetes mellitus (T2DM) and coronary artery disease (CAD). The effect of dipeptidyl …
diabetes mellitus (T2DM) and coronary artery disease (CAD). The effect of dipeptidyl …
Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis—A review
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of
anti-diabetic drugs that have therapeutic potential in the management of atherosclerosis. Of …
anti-diabetic drugs that have therapeutic potential in the management of atherosclerosis. Of …